This thesis investigates the feasibility of using a complex model with a Monte Carlo simulation model to forecast the financial, personnel, and manufacturing capacity resources needed for biologic drug development. Accurate forecasting is integral across industries in order to make strong long-term, strategic decisions and an area many companies struggle with. The resources required for the development of a biologic drug are especially hard to estimate due to the variability in the time and probability of success of each development phase. However, in the pharmaceutical industry getting products to market faster allows the company more time to recoup the substantial development investments before the patent expires and also potentially has ...
Current pressures of cost and speed to market are driving the need for more effective means of asses...
The development of a new drug is an extremely high-risk enterprise. The attrition rates of developme...
In this paper, we develop a stochastic simulation model for biomanufacturing risk analysis by focusi...
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Mas...
Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2014. In conjunct...
The need for Clinical and Commercial manufacturing capacity continues to increase and at the same ti...
The task of quickly bringing novel pharmaceutical products to market at reasonable cost is daunting....
Healthcare remains a national crisis. Among the associated issues are the high cost of medications a...
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Mas...
Whilst many cell therapy products have been approved over the last 20 years, very few have achieved ...
Biopharmaceutical drug development is risky, lengthy, and expensive. Decisions in this delicate proc...
Clinical trials are forthcoming biomedical or behavioral research studies on human participants, des...
Biopharmaceutical manufacturing mainly produces large molecule-based products and is becoming increa...
AbstractWith the increase in demand for biopharmaceutical products, industries have realised the nee...
The therapeutic monoclonal antibody (mAb) market is witnessing an unprecedented growth having nearly...
Current pressures of cost and speed to market are driving the need for more effective means of asses...
The development of a new drug is an extremely high-risk enterprise. The attrition rates of developme...
In this paper, we develop a stochastic simulation model for biomanufacturing risk analysis by focusi...
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Mas...
Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2014. In conjunct...
The need for Clinical and Commercial manufacturing capacity continues to increase and at the same ti...
The task of quickly bringing novel pharmaceutical products to market at reasonable cost is daunting....
Healthcare remains a national crisis. Among the associated issues are the high cost of medications a...
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Mas...
Whilst many cell therapy products have been approved over the last 20 years, very few have achieved ...
Biopharmaceutical drug development is risky, lengthy, and expensive. Decisions in this delicate proc...
Clinical trials are forthcoming biomedical or behavioral research studies on human participants, des...
Biopharmaceutical manufacturing mainly produces large molecule-based products and is becoming increa...
AbstractWith the increase in demand for biopharmaceutical products, industries have realised the nee...
The therapeutic monoclonal antibody (mAb) market is witnessing an unprecedented growth having nearly...
Current pressures of cost and speed to market are driving the need for more effective means of asses...
The development of a new drug is an extremely high-risk enterprise. The attrition rates of developme...
In this paper, we develop a stochastic simulation model for biomanufacturing risk analysis by focusi...